Patents Examined by Kamal Saeed
  • Patent number: 11518741
    Abstract: The present invention relates to a brivaracetam intermediate, a preparation method therefor, and a preparation method for brivaracetam. The steps of the method for preparing brivaracetam described in the present invention are short and the raw materials are cheap, moreover, the method is simple and highly effective without requiring isomer separation by means of column chromatography or asymmetric synthesis, being suitable for industrial large-scale production. In addition, disclosed by the present invention is a compound as shown in formula (II), which may be used for the synthesis of brivaracetam.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: December 6, 2022
    Assignee: SHANGHAI PUYI CHEMICAL CO., LTD.
    Inventors: Hanrong Yang, Yantao Qi, Tao Li, Bo Wang
  • Patent number: 11518748
    Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 6, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Jonathan S. Stamler, William Greenlee, Focco van den Akker
  • Patent number: 11510908
    Abstract: Provided herein are protein translation inhibitors and pharmaceutical compositions thereof that bind to an RNA Recognition motif in heterogeneous ribonucleoprotein A18 to inhibit binding to mRNA transcripts thereby inhibiting protein synthesis. Also provided is a method for treating a cancer by administering a pharmaceutically acceptable amounts of at least one of the protein translation inhibitors.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: November 29, 2022
    Assignee: University of Maryland, Baltimore
    Inventors: France Carrier, Alexander D. MacKerell, David J. Weber, Wenbo Yu
  • Patent number: 11510914
    Abstract: A method of inhibiting a rise in intraneuronal calcium concentration includes administering an effective amount of a cyclic amine derivative represented by formula (I) or a pharmacologically acceptable salt thereof to a subject in need thereof: wherein A represents formula (IIa), (IIb) or (IIc):
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 29, 2022
    Assignee: Toray Industries, Inc.
    Inventors: Kanako Serizawa, Kazumi Nishimura, Tomohiko Suzuki, Tatsuya Nishi
  • Patent number: 11505533
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 22, 2022
    Assignees: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • Patent number: 11497719
    Abstract: Disclosed are a cannabinoid composition and an application of the same in preparing a medicine for treating neurodegenerative diseases, so as to solve the drawbacks of conventional medicines such as serious side effects and degraded therapeutic effect after long-term administration. The cannabinoid composition includes: cannabidiol and cannabigerol, a mass ratio of the cannabidiol to the cannabigerol ranging from 1:1 to 1:10, or from 1:0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:07 to 1:1.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 15, 2022
    Inventors: Chendong Zou, Hei Tai, Guijiang Wang, Wan Xiao, Sui Huang
  • Patent number: 11497731
    Abstract: An object is to provide a compound having ?-lactamase inhibitory activity. The object is achieved by a compound represented by formula (1), typified by a compound in which specific positions of a 5-membered ring having planarity are replaced by sulfamoyl and carboxy groups.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: November 15, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
    Inventors: Yoshichika Arakawa, Jun-ichi Wachino, Kouji Kimura, Wan Chun Jin, Ayato Sato
  • Patent number: 11497734
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 15, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty S. Naremaddepalli, Nagaraj Gowda
  • Patent number: 11491169
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: November 8, 2022
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Patent number: 11492349
    Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: November 8, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Patent number: 11471441
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: October 18, 2022
    Assignee: Loxo Oncology Inc.
    Inventor: Nicolas Guisot
  • Patent number: 11472816
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: October 18, 2022
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • Patent number: 11471444
    Abstract: Thromboxane A2 receptor antagonists, such as ifetroban, inhibit solid tumor metastasis. The formation of surface and microscopic lung metastases are inhibited. Thromboxane A2 receptor antagonists can inhibit the tumor metastasis process without affecting the growth or development of a primary tumor.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: October 18, 2022
    Assignee: Vanderbilt University
    Inventors: Jill M. Pulley, Robert R. Lavieri
  • Patent number: 11472781
    Abstract: The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: October 18, 2022
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventors: Mark J. Suto, Bini Mathew, Rita Cowell, Corinne E. Augelli-Szafran
  • Patent number: 11465999
    Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: October 11, 2022
    Assignee: FRESENIUS KABI ONCOLOGY LTD.
    Inventors: Vinod Singh Tomar, Abul Azim, Nitin Gupta, Saswata Lahiri, Walter Cabri
  • Patent number: 11458121
    Abstract: Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: October 4, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Edmond J. LaVoie, Ajit Parhi, Hye Yeon Sagong
  • Patent number: 11459320
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: October 4, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Patent number: 11447445
    Abstract: N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 20, 2022
    Assignees: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität Frankfurt
    Inventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
  • Patent number: 11440905
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: September 13, 2022
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Patent number: 11419852
    Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: August 23, 2022
    Assignee: GLYCOLYSIS BIOMED CO., LTD.
    Inventors: Feng-Ling Lee, Lung-Jr Lin, Jyh-Shing Hsu, Cheng-Hsien Hsu, Yen-Chun Huang, Ya-Chien Huang, Chun-Tsung Lo, Hui-Fang Liao, Yu-Wen Liu, Yu-Chi Kao